LIGAND PHARMACEUTICALS INCORPORATED Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 58.00% for the 12-month period ending 2015-12-31, per its 10-K filed 2016-11-14.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2016-11-14
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2015 was 58.00%, a 15.94% decline from fiscal 2014.
- LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2014 was 69.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month |
|---|---|---|
| 2015-12-31 | 58.00% 10-K · filed 2016-11-14 | |
| 2015-09-30 | 58.00% 10-Q · filed 2015-11-09 | |
| 2014-12-31 | 69.00% 10-K · filed 2016-11-14 |